SUNLOCSunil Healthcare Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Sunil Healthcare Limited engages in the manufacture and sale of empty hard gelatin, hydroxypropyl methylcellulose (HPMC), and pullulan capsules shells in India and internationally. Its products include EHG, BSE/TSE free, pearl, liquid fill, preservative free, stick free, flavored, SLS free, natural color, non-AZO, gelatin, HPMC/vegetable, and pullulan capsules. The company also provides ayurvedic products, such as haldi, ginger, vasaka, trifala, guduchi, salaki, punarvana, shatavari, hadjod, hingwastak, mulethi, arjuna, ashwagandha, and guggul extracts. The company offers its products under the SUNLOC brand name. Sunil Healthcare Limited was incorporated in 1973 and is based in New Delhi, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on SUNLOC — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Debt/Equity: 0.80
- • Promoter holding: 88.2%
- • Valuation vs sector: P/E 21.8 vs sector 40.5
- • Distance from 52-week high: 7.9% below high
- • Volume trend: 1.6x baseline
- • Sector momentum: sector +6.2% (1m)
Bull case
- • Debt/Equity: 0.80
- • Promoter holding: 88.2%
- • Valuation vs sector: P/E 21.8 vs sector 40.5
- • Distance from 52-week high: 7.9% below high
Bear case
- • Recently listed — limited trading history, scores are provisional
- • Revenue growth: -16.1% YoY
- • Profit growth: -49.4% YoY
- • Insufficient price history
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Recently listed — limited trading history, scores are provisional
- • Revenue growth: -16.1% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹3.64). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.